Treatment Options and Supportive Care
At a Glance
Fucosidosis has no approved enzyme replacement or gene therapy, so care focuses on individualized support for breathing, infections, swallowing, nutrition, mobility, comfort, and quality of life. HSCT remains experimental, with uncertain benefits and serious risks.
Managing fucosidosis focuses on supportive care to manage daily symptoms and improve quality of life. At this time, there is no approved Enzyme Replacement Therapy (ERT) or gene therapy for fucosidosis [1]. While ERT has been studied in animals, a major challenge is the blood-brain barrier—a protective layer that prevents many treatments from reaching the brain and central nervous system, where they are needed most [1][2].
Hematopoietic Stem Cell Transplantation (HSCT)
Commonly known as a bone marrow or cord blood transplant, HSCT is currently an experimental and uncertain option that may be considered by specialized metabolic/transplant teams. In a few documented case reports, children who received a transplant early in life showed stabilization of white-matter changes on MRI or gradual improvement [3][4].
However, HSCT is not an established, proven treatment for fucosidosis, and the decision to pursue it is deeply complex.
The Therapeutic Window
HSCT has typically only been considered during a very narrow window—typically early in the disease before significant or irreversible brain damage has occurred [5][3]. If substantial neurologic decline has already happened, the risks of the procedure may outweigh any unproven benefits [6].
Risks and Trade-offs
Transplantation is a major medical undertaking with significant, life-threatening risks:
- Transplant-Related Mortality: There is a significant risk of death from the procedure itself due to infection, organ failure, or other complications [6][7].
- Graft-Versus-Host Disease (GVHD): This occurs when the new donor cells attack the recipient’s body, which can lead to long-term health issues [7].
- Conditioning Effects: The intensive chemotherapy required before a transplant can cause infertility, growth issues, and severe vulnerability to infections [5][8].
Because outcomes are mixed and no disease-modifying benefit is definitively proven, discussions about HSCT must take place with an experienced metabolic transplant center that can provide an individualized risk assessment.
Multi-System Supportive Care
Regardless of whether experimental treatments are pursued, every individual with fucosidosis requires a coordinated team of specialists to manage the physical symptoms of the disease. Supportive care is standard for everyone [9].
Respiratory and Infection Management
Because individuals with fucosidosis are prone to frequent infections and pneumonia, protecting the lungs is a priority [10]. Doctors may recommend:
- Targeted Treatment: Using antibiotics appropriately when a bacterial infection is suspected or confirmed by a clinician, guided by a written respiratory action plan [10].
- Clearance Interventions: Airway clearance devices (like a cough assist) or chest physiotherapy [11] should be individualized interventions prescribed and taught by a respiratory team.
Nutrition and Swallowing Safety
As the disease progresses, the muscles used for swallowing can weaken, leading to aspiration (food, liquid, or saliva entering the lungs) [12].
- Feeding Assessments: Swallowing evaluations, such as instrumental swallow studies, should be symptom- and risk-based, guided by a speech-language or feeding specialist.
- Feeding Tubes (G-tubes): If swallowing becomes unsafe or nutrition is inadequate, a feeding tube can provide essential hydration directly to the stomach [13][14]. It is important to know that a G-tube does not eliminate the risk of aspirating saliva or reflux.
Mobility and Comfort
Physical and Occupational Therapy (PT and OT) are essential for maintaining comfort and function [13].
- Muscle Management: Prescribed exercises can help manage spasticity and prevent painful contractures (permanent tightening of the muscles or joints) [15].
- Adaptive Equipment: Specialized seating or mobility aids help individuals stay engaged with their family and surroundings.
Palliative Care: A Layer of Support
Many families find it helpful to involve a palliative care team early in the diagnosis. Palliative care is not just for the end of life; it is a specialized medical service that focuses on relieving symptoms, managing pain, and helping families coordinate their care goals to ensure the best possible quality of life [9][16].
Common questions in this guide
What treatments are available for fucosidosis?
Is hematopoietic stem cell transplantation a proven treatment for fucosidosis?
When might HSCT be considered for fucosidosis?
How can swallowing problems and aspiration be managed?
What supportive care can help with breathing and respiratory infections?
How can palliative care help someone with fucosidosis?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
Treatment options
Would HSCT be considered for us, and what are its risks?
Risks and trade-offs
What would a metabolic transplant center assess about HSCT risks?
Supportive care
Could a feeding tube or airway clearance be part of our supportive care?
Get notified when new evidence is published on Fucosidosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (16)
- 1
Fucosidosis: A Review of a Rare Disease.
Pekdemir B, Bechelany M, Karav S
International journal of molecular sciences 2025; (26(1)) doi:10.3390/ijms26010353.
PMID: 39796208 - 2
The effects of intracisternal enzyme replacement versus sham treatment on central neuropathology in preclinical canine fucosidosis.
Kondagari GS, Fletcher JL, Cruz R, et al.
Orphanet journal of rare diseases 2015; (10()):143 doi:10.1186/s13023-015-0357-z.
PMID: 26537923 - 3
Early Hematopoietic Stem Cell Transplantation in Type 1 Fucosidosis: Reversal of Central Tegmental Tract Abnormalities.
Palaz M, Taşkın A, Özpınar E, et al.
Pediatric transplantation 2026; (30(10)):e70502 doi:10.1111/petr.70502.
PMID: 42888855 - 4
Brain abnormalities in fucosidosis: transplantation or supportive therapy?
Jiang M, Liu S, Jiang H, et al.
Metabolic brain disease 2017; (32(2)):317-320 doi:10.1007/s11011-017-9968-5.
PMID: 28238202 - 5
Therapy Development for the Lysosomal Storage Disease Fucosidosis using the Canine Animal Model.
Fletcher JL, Taylor RM
Pediatric endocrinology reviews : PER 2016; (13 Suppl 1()):697-706.
PMID: 27491218 - 6
Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Juvenile Metachromatic Leukodystrophy Compared With Nontransplanted Control Patients.
Groeschel S, Kühl JS, Bley AE, et al.
JAMA neurology 2016; (73(9)):1133-40 doi:10.1001/jamaneurol.2016.2067.
PMID: 27400410 - 7
Survival and Functional Outcomes in Boys with Cerebral Adrenoleukodystrophy with and without Hematopoietic Stem Cell Transplantation.
Raymond GV, Aubourg P, Paker A, et al.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2019; (25(3)):538-548 doi:10.1016/j.bbmt.2018.09.036.
PMID: 30292747 - 8
Hematopoietic Stem Cell Transplantation to Treat Leukodystrophies: Clinical Practice Guidelines from the Hunter's Hope Leukodystrophy Care Network.
Page KM, Stenger EO, Connelly JA, et al.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2019; (25(12)):e363-e374 doi:10.1016/j.bbmt.2019.09.003.
PMID: 31499213 - 9
Diagnosis and Supportive Management of Fucosidosis: A Case Report.
Kaur A, Dhaliwal AS, Raynes H, et al.
Cureus 2019; (11(11)):e6139 doi:10.7759/cureus.6139.
PMID: 31886074 - 10
Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series.
Stepien KM, Ciara E, Jezela-Stanek A
Genes 2020; (11(11)) doi:10.3390/genes11111383.
PMID: 33266441 - 11
Recalcitrant chronic rhinosinusitis in the setting of fucosidosis, a rare lysosomal storage disorder.
Peng T, Modi VK, Pearlman AN
International journal of pediatric otorhinolaryngology 2017; (103()):5-9 doi:10.1016/j.ijporl.2017.09.019.
PMID: 29224764 - 12
Novel FUCA1 variants in two families, including the first report of a contiguous gene deletion syndrome involving FUCA1 and HMGCL.
Kılıç M, Yıldız H, Dinçsoy Bir F
The Turkish journal of pediatrics 2025; (67(6)):896-903 doi:10.24953/turkjpediatr.2025.6009.
PMID: 41636194 - 13
Long-term outcomes in two adult siblings with Fucosidosis - Diagnostic odyssey and clinical manifestations.
Puente-Ruiz N, Ellis I, Bregu M, et al.
Molecular genetics and metabolism reports 2023; (37()):101009 doi:10.1016/j.ymgmr.2023.101009.
PMID: 38053939 - 14
An unusual presentation of fucosidosis in a Chinese boy: a case report and literature review (childhood fucosidosis).
Mao SJ, Zhao J, Shen Z, Zou CC
BMC pediatrics 2022; (22(1)):403 doi:10.1186/s12887-022-03414-y.
PMID: 35820891 - 15
Clinical and neuroradiological approach to fucosidosis in a child with atypical presentation.
Zubarioglu T, Kiykim E, Zeybek CA, et al.
Annals of Indian Academy of Neurology 2015; (18(4)):471-4 doi:10.4103/0972-2327.160090.
PMID: 26713028 - 16
Late Effects in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation for Nonmalignant Diseases: Proxy- and Patient-Reported Outcomes.
Bense JE, Haverman L, von Asmuth EGJ, et al.
Transplantation and cellular therapy 2023; (29(3)):186.e1-186.e10 doi:10.1016/j.jtct.2022.12.024.
PMID: 36587742
This page explains supportive care and experimental treatment considerations for fucosidosis for educational purposes only and does not replace medical advice. Decisions about HSCT, respiratory care, feeding, and symptom management should be made with the patient’s specialized care team.